Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AbbVie Inc.
US Infant Formula Supply Chain Strategy Delivered
FDA immediate actions include ensuring providers know they’re required to develop redundancy risk management plans, enhancing inspections of manufacturers, including by expanding and improving training for investigators, and expediting reviews of premarket submissions for new products.
FDA Report On US Formula Supply Doesn’t Stop Criticism From Congress, Former Food Policy Chief
On same day agency published strategy for ensuring formula supply, House Oversight Committee subcommittee members made clear they’re not convinced FDA could prevent repeat of 2022 shortage. Recently resigned FDA food policy chief also has doubts.
Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing
US Solicitor General urges the Supreme Court to grant Teva's petition, arguing that the Federal Circuit was wrong in ruling that Teva's carved-out labeling for generic carvedilol induced infringement of GlaxoSmithKine's brand product.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
- Other Names / Subsidiaries
- Pharmacyclics, Inc.
- Stemcentrx, Inc.
- Syndesi Therapeutics SA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.